Poland· PL-100393858
Atosiban Mercapharm
A atosiban product containing atosibanum, registered in Poland by Mercapharm Sp. z o.o.. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Atosiban is registered in 14 of 19 countries.
Countries holding a registration under ATC G02CX01 (atosiban), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Atosiban · ATC G02CX01
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
The record
At a glance
URPL (Poland)- Active substance
- Atosibanum
- Manufacturer
- Mercapharm Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- G02CX01
- ATC class
- Atosiban
- Defined daily dose
- 165 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991429935
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Atosiban in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandAtosiban AccordAccord Healthcare B.V.
- SwedenAtosiban Accord 37,5 mg/5 ml Koncentrat till infusionsvätska, lösningAccord Healthcare B.V.
- BelgiumAtosiban Ever Pharma 37.5 mg/5 mlEVER Valinject
- CzechiaATOSIBAN AVMCAV Medical CZ s.r.o., Praha
- NorwayAtosiban AccordAccord Healthcare B.V.
- SwitzerlandAtosiban Labatec 37.5 mg / 5 ml, solution à diluer pour perfusionLabatec Pharma SA
- IcelandAtosiban SUNSun Pharmaceutical Industries Europe B.V.*
- IrelandAtosiban SUN 37.5 mg/5 ml concentrate for solution for infusionSun Phamaceutical Industries Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 23 EEA countries. Names it is sold under:
- Austria · Atosiban Altan, Atosiban Ever Pharma
- Belgium · Atosiban Ever Pharma
- Bulgaria · Атозибан Ever Pharma
- Czechia · Atosiban Avmc, Atosiban Ever Pharma
- Germany · Atosiban Ever Pharma, Atosiban Ibisqus
- Denmark · Atosiban Ever Pharma
- Spain · Atosiban Altan Pharmaceuticals, S.A., Atosiban Ever Pharma
- Finland · Atosiban Ever Pharma
- France · Atosiban Altan, Atosiban Altan Pharmaceuticals, S.A.
- United Kingdom (Northern Ireland) · Atosiban Ibigen
- Greece · Atosiban Ever Pharma
- Croatia · Atosiban Ever Pharma, Atosiban Makpharm
- Iceland · Atosiban Sun, Tractocile
- Italy · Atosiban Ever Pharma, Atosiban Ibisqus
- Liechtenstein · Tractocile
- Luxembourg · Atosiban Ever Pharma
- Latvia · Atosiban Pharmidea
- Netherlands · Atosiban Accord, Atosiban Ever Pharma
- Norway · Atosiban Ever Pharma, Atosiban Sun
- Portugal · Atosiban Ever Pharma, Atosibano Altan
- Sweden · Atosiban Accord, Atosiban Ever Pharma
- Slovenia · Atoziban Ever Pharma
- Slovakia · Atosiban Ardez
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c282aa19-533d-4325-b58e-c8b9d418d3c7 GET /v1/drugs/c282aa19-533d-4325-b58e-c8b9d418d3c7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "37,5 mg/5 ml",
"packaging": "05909991429935 ¦ Rpz ¦ 136349\n1 fiol. 5 ml",
"substance": "Atosibanum 37,5 mg/5 ml",
"common_name": "Atosibanum",
"pl_product_id": "100393858",
"pozwolenie_nr": "25873",
"auth_procedure": "MRP",
"authorisation_validity": "2025-01-17"
}See everything about atosiban.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.